Bank of New York Mellon Corp Sells 27,653 Shares of Charles River Laboratories International, Inc. (CRL)

Bank of New York Mellon Corp decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 812,990 shares of the medical research company’s stock after selling 27,653 shares during the period. Bank of New York Mellon Corp owned approximately 1.71% of Charles River Laboratories International worth $87,819,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of CRL. Oregon Public Employees Retirement Fund increased its position in Charles River Laboratories International by 4.6% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 17,199 shares of the medical research company’s stock worth $1,740,000 after buying an additional 753 shares during the period. LS Investment Advisors LLC increased its position in Charles River Laboratories International by 17.1% during the 2nd quarter. LS Investment Advisors LLC now owns 3,971 shares of the medical research company’s stock worth $402,000 after buying an additional 580 shares during the period. Aperio Group LLC increased its position in Charles River Laboratories International by 5.6% during the 2nd quarter. Aperio Group LLC now owns 23,406 shares of the medical research company’s stock worth $2,368,000 after buying an additional 1,236 shares during the period. State Treasurer State of Michigan increased its position in Charles River Laboratories International by 2.1% during the 2nd quarter. State Treasurer State of Michigan now owns 19,600 shares of the medical research company’s stock worth $1,983,000 after buying an additional 400 shares during the period. Finally, ING Groep NV bought a new position in Charles River Laboratories International during the 2nd quarter worth $586,000. Hedge funds and other institutional investors own 98.72% of the company’s stock.

Several analysts have recently issued reports on CRL shares. BidaskClub lowered Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 target price on the stock in a report on Thursday, August 10th. Robert W. Baird reissued a “buy” rating and set a $114.00 target price on shares of Charles River Laboratories International in a report on Friday, September 1st. Jefferies Group LLC reissued a “buy” rating and set a $120.00 target price on shares of Charles River Laboratories International in a report on Tuesday, September 12th. Finally, Royal Bank Of Canada started coverage on Charles River Laboratories International in a report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 target price on the stock. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $106.63.

Charles River Laboratories International, Inc. (NYSE:CRL) traded down $0.49 on Monday, hitting $101.80. The stock had a trading volume of 129,600 shares, compared to its average volume of 379,431. The firm has a market cap of $4,820.00, a price-to-earnings ratio of 20.00, a P/E/G ratio of 1.62 and a beta of 0.94. Charles River Laboratories International, Inc. has a 12 month low of $69.51 and a 12 month high of $119.05. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.08. The company had revenue of $464.23 million for the quarter, compared to analyst estimates of $458.93 million. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. Charles River Laboratories International’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.18 EPS. equities analysts anticipate that Charles River Laboratories International, Inc. will post 5.13 EPS for the current year.

In related news, insider Davide Molho sold 6,165 shares of the firm’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $110.00, for a total value of $678,150.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $0.27, for a total value of $270,000.00. Over the last ninety days, insiders purchased 10,500 shares of company stock worth $2,885 and sold 1,012,147 shares worth $1,591,514. Company insiders own 2.20% of the company’s stock.

WARNING: “Bank of New York Mellon Corp Sells 27,653 Shares of Charles River Laboratories International, Inc. (CRL)” was first reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://transcriptdaily.com/2017/11/27/bank-of-new-york-mellon-corp-sells-27653-shares-of-charles-river-laboratories-international-inc-crl.html.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply